| 1 |
31421661 | The utility of surrogate markers in predicting HLA alleles associated with adverse drug reactions in Vietnamese. | 2022 Jun |
3 |
| 2 |
34350628 | Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine. | 2022 Feb |
2 |
| 3 |
34553372 | HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese. | 2022 Feb |
6 |
| 4 |
35070271 | Reducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes. | 2022 Jan |
2 |
| 5 |
35170024 | Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti-seizure medications. | 2022 Apr |
1 |
| 6 |
35187767 | Association between human leukocyte antigens and cutaneous adverse drug reactions to antiepileptics and antibiotics in the Iranian population. | 2022 May |
1 |
| 7 |
35230712 | Incidence of Antiseizure Medication-Induced Severe Cutaneous Adverse Reactions in Malaysia. | 2022 Mar 1 |
1 |
| 8 |
35450046 | Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand. | 2022 |
1 |
| 9 |
35496269 | Single Nucleotide Variants as Proxies for HLA-A*31:01 in Native American Populations. | 2022 |
1 |
| 10 |
35526384 | Carbamazepine-modified HLA-A*24:02-bound peptidome: Implication of CORO1A in skin rash. | 2022 Aug |
4 |
| 11 |
35568130 | Weak complex formation of adverse drug reaction-associated HLAB57, B58, and B15 molecules. | 2022 Aug |
1 |
| 12 |
35599240 | Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis. | 2022 May 22 |
11 |
| 13 |
32909461 | Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice. | 2021 Jan-Feb |
2 |
| 14 |
32937013 | Association of the HLA-B*15:02 allele with pure cervical lymphadenopathy induced by carbamazepine and oxcarbazepine: A case report and literature review. | 2021 Feb |
1 |
| 15 |
33147643 | Review and Consensus on Pharmacogenomic Testing in Psychiatry. | 2021 Jan |
1 |
| 16 |
33231367 | An alarm system of carbamazepine-induced toxic effects highly associated with HLA-B*1502 allele. | 2021 Feb |
1 |
| 17 |
33356553 | Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese. | 2021 Jan |
3 |
| 18 |
33608873 | Carbamazepine-induced toxic epidermal necrolysis: the importance of HLA-B*1502 testing in at-risk populations prior to therapy initiation. | 2021 Jul |
1 |
| 19 |
33824430 | Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model. | 2021 Aug |
3 |
| 20 |
33848012 | Stevens-Johnson syndrome and toxic epidermal necrolysis in a referral center in Taiwan. | 2021 Aug |
2 |
| 21 |
33910375 | HLA-A*24:07 as a potential biomarker for carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Filipino patients. | 2021 Jun |
2 |
| 22 |
33912179 | Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition. | 2021 |
2 |
| 23 |
34092825 | Lamotrigine and Stevens-Johnson Syndrome Prevention. | 2021 Mar 16 |
1 |
| 24 |
34105877 | HLA-associated adverse drug reactions - scoping review. | 2021 Sep |
1 |
| 25 |
34122097 | HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema. | 2021 |
1 |
| 26 |
34153177 | Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. | 2021 Nov |
1 |
| 27 |
34381365 | Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds. | 2021 |
1 |
| 28 |
34442381 | Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population. | 2021 Jul 28 |
1 |
| 29 |
34652573 | Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. | 2021 Oct 15 |
2 |
| 30 |
31784043 | CD39+ regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02 carriers. | 2020 Jan |
5 |
| 31 |
31896765 | Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. | 2020 Jun |
5 |
| 32 |
32099830 | Drug hypersensitivity reactions in Asia: regional issues and challenges. | 2020 Jan |
1 |
| 33 |
32100936 | Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. | 2020 Sep |
1 |
| 34 |
32180714 | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics. | 2020 |
2 |
| 35 |
32457602 | Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care. | 2020 |
1 |
| 36 |
32714190 | Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. | 2020 |
1 |
| 37 |
33071783 | Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. | 2020 |
1 |
| 38 |
29800753 | Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. | 2019 Jan |
1 |
| 39 |
29858578 | Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. | 2019 Feb |
1 |
| 40 |
30573342 | Controversies in drug allergy: Testing for delayed reactions. | 2019 Jan |
1 |
| 41 |
30826555 | Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. | 2019 Mar |
1 |
| 42 |
30971914 | A Screening Test for HLA-B∗15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events. | 2019 |
4 |
| 43 |
30972788 | HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. | 2019 Nov |
1 |
| 44 |
31158306 | Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. | 2019 Jul |
1 |
| 45 |
31198488 | Developing pharmacogenetic screening methods for an emergent country: Vietnam. | 2019 |
4 |
| 46 |
31263447 | HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity? | 2019 |
2 |
| 47 |
31395875 | Identification of drug-specific public TCR driving severe cutaneous adverse reactions. | 2019 Aug 8 |
2 |
| 48 |
31618895 | The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity. | 2019 Oct 15 |
2 |
| 49 |
31736555 | Diagnostic Utility of Human Leukocyte Antigen B*15:02 Screening in Severe Carbamazepine Hypersensitivity Syndrome. | 2019 Oct-Dec |
5 |
| 50 |
28440597 | External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy. | 2018 Feb |
1 |